他莫昔芬及其代谢产物血药浓度与ER阳性乳腺癌患者子宫内膜增生的相关性研究
发布时间：2018-10-14 08:42
【摘要】：目的:考察他莫昔芬(TAM)及其代谢产物血药浓度与雌激素受体(ER)阳性乳腺癌患者子宫内膜增生的相关性。方法:选取2015年3月-2016年4月我院ER阳性乳腺癌患者69例,均接受TAM持续治疗半年以上(每日2次,每次1片)。根据治疗后其子宫内膜厚度分为异常增生组(40例)和正常组(29例),采用高效液相色谱-荧光法测定其体内TAM及代谢产物[4-羟基他莫昔芬(OHT)、N-去甲基他莫昔芬(DMT)和Endoxifen]的稳态血药浓度,采用Pearson检验和多元回归分析考察血药浓度等因素与子宫内膜厚度的相关性。结果:异常增生组患者的用药时间、Endoxifen稳态血药浓度均显著长于或高于正常组,差异均有统计学意义(P0.05);而两组患者年龄,体质量指数,并发症以及TAM、OHT、DMT稳态血药浓度比较,差异均无统计学意义(P0.05)。患者子宫内膜厚度与Endoxifen稳态血药浓度和用药时间呈正相关性(r分别为0.447、0.460,P0.05);以子宫内膜厚度(y)为因变量,用药时间(x_1)和Endoxifen稳态血药浓度(x_2)为自变量,进行多元回归分析,得回归方程为y=2.436+0.123x_1+0.082x_2(F=12.610,r=0.526,P0.05)。结论:Endoxifen稳态血药浓度和患者用药时间可能与子宫内膜增生有关,可为临床预测TAM致ER阳性乳腺癌患者子宫内膜异常增生提供参考。
[Abstract]:Aim: to investigate the relationship between serum concentration of tamoxifen (TAM) and its metabolites and endometrial hyperplasia in patients with estrogen receptor (ER) positive breast cancer. Methods: 69 patients with ER positive breast cancer in our hospital from March 2015 to April 2016 were treated with TAM for more than half a year (1 tablet twice a day). According to the thickness of endometrium after treatment, the endometrium was divided into two groups: abnormal hyperplasia group (40 cases) and normal group (29 cases). TAM and its metabolites [4-hydroxytamoxifene (OHT), N-demethamoxifene (DMT) and Endoxifen] were determined by high performance liquid chromatography-fluorescence method. Steady-state blood drug concentration, The correlation between blood drug concentration and endometrial thickness was investigated by Pearson test and multiple regression analysis. Results: the drug use time and Endoxifen steady-state concentration in patients with abnormal hyperplasia were significantly longer than or higher than those in normal controls (P0.05), while the age, body mass index, complications and steady-state serum concentration of TAM,OHT,DMT were compared between the two groups. The difference was not statistically significant (P0.05). The endometrial thickness was positively correlated with the steady-state serum concentration and duration of Endoxifen (r = 0.4470.460,0.05), the endometrial thickness of (y) was taken as dependent variable, the time of administration (xStu1) and the steady-state blood drug concentration of Endoxifen (x2) were used as independent variables, and the multivariate regression analysis was carried out. The regression equation was 2.436 0.123x_1 0.082x_2 (F _ (12. 610) ~ 0. 526 ~ 0. 05). Conclusion: the steady-state blood concentration of Endoxifen and the duration of treatment may be related to endometrial hyperplasia, which may provide a reference for clinical prediction of abnormal hyperplasia of endometrium in patients with ER positive breast cancer induced by TAM.
【作者单位】： 南京医科大学附属南京医院/南京市第一医院药学部;
【基金】：江苏省药学会奥赛康临床药学立项课题(No.201209)
【分类号】：R969
本文编号：2269952
[Abstract]:Aim: to investigate the relationship between serum concentration of tamoxifen (TAM) and its metabolites and endometrial hyperplasia in patients with estrogen receptor (ER) positive breast cancer. Methods: 69 patients with ER positive breast cancer in our hospital from March 2015 to April 2016 were treated with TAM for more than half a year (1 tablet twice a day). According to the thickness of endometrium after treatment, the endometrium was divided into two groups: abnormal hyperplasia group (40 cases) and normal group (29 cases). TAM and its metabolites [4-hydroxytamoxifene (OHT), N-demethamoxifene (DMT) and Endoxifen] were determined by high performance liquid chromatography-fluorescence method. Steady-state blood drug concentration, The correlation between blood drug concentration and endometrial thickness was investigated by Pearson test and multiple regression analysis. Results: the drug use time and Endoxifen steady-state concentration in patients with abnormal hyperplasia were significantly longer than or higher than those in normal controls (P0.05), while the age, body mass index, complications and steady-state serum concentration of TAM,OHT,DMT were compared between the two groups. The difference was not statistically significant (P0.05). The endometrial thickness was positively correlated with the steady-state serum concentration and duration of Endoxifen (r = 0.4470.460,0.05), the endometrial thickness of (y) was taken as dependent variable, the time of administration (xStu1) and the steady-state blood drug concentration of Endoxifen (x2) were used as independent variables, and the multivariate regression analysis was carried out. The regression equation was 2.436 0.123x_1 0.082x_2 (F _ (12. 610) ~ 0. 526 ~ 0. 05). Conclusion: the steady-state blood concentration of Endoxifen and the duration of treatment may be related to endometrial hyperplasia, which may provide a reference for clinical prediction of abnormal hyperplasia of endometrium in patients with ER positive breast cancer induced by TAM.
【作者单位】： 南京医科大学附属南京医院/南京市第一医院药学部;
【基金】：江苏省药学会奥赛康临床药学立项课题(No.201209)
【分类号】：R969
【相似文献】
相关期刊论文 前1条
1 何芳;宋淑芬;何慧;;个案管理模式对ER阳性乳腺癌生命质量的影响研究[J];齐齐哈尔医学院学报;2014年09期
相关硕士学位论文 前1条
1 陈慧;ER阳性乳腺癌辅助内分泌治疗耐药的相关因素及血清miRNAs的研究[D];南京大学;2015年
，本文编号：2269952
本文链接：https://www.wllwen.com/yixuelunwen/yiyaoxuelunwen/2269952.html
最近更新
教材专著
